Group 1: Industry Developments - China's medical isotope self-sufficiency has made significant progress, with the establishment of a complete eco-friendly autonomous industrial chain for iodine-131 production, including precursor preparation, reactor irradiation, and nuclear drug development [1] - The global nuclear medicine market is projected to reach nearly $39 billion by 2032, indicating strong growth potential in the sector [1] - The number of approved radiotherapy devices in China has exceeded 90, with over 70% being domestically produced, marking a shift from reliance on imports [2] Group 2: Company Updates - China National Nuclear Corporation's subsidiary, Atomic High-Tech Co., has signed a commercial cooperation agreement with Novartis for the radioligand therapy drug, which is the first approved targeted PSMA therapy for advanced prostate cancer in China [3] - Yuan Da Pharmaceutical has 15 innovative nuclear drugs in the R&D registration phase, with a significant revenue increase in its nuclear medicine segment, achieving approximately HKD 420 million in revenue, a year-on-year growth of nearly 106% [3] - Sillod Medical has completed the first patient dosing in a study for its radiolabeled drug, 177Lu-PSMA-3D1015, aimed at treating metastatic castration-resistant prostate cancer, positioning it as a potential best-in-class product [4]

Group 1: Medical Isotope Production - China National Nuclear Corporation (CNNC) has successfully developed a complete technology chain for the irradiation preparation of iodine-131, enhancing the self-sufficiency of medical isotopes in China [1] - The technology includes the preparation of precursor isotopes, reactor irradiation, and nuclear drug development, forming an environmentally friendly and autonomous industrial chain [1] - The successful production of high-purity tellurium-130 isotopes with over 99% abundance fills a gap in the domestic large-scale preparation of high-purity enriched tellurium isotopes [1] Group 2: Radiation Therapy Equipment and Drug Development - As of 2024, over 90 radiotherapy devices have been approved by the National Medical Products Administration, with more than 70% being domestic brands, significantly reducing reliance on imported equipment [2] - The development of new radiopharmaceuticals has accelerated, with over 200 pipelines entering clinical trials, introducing new isotopes like lutetium-177 and yttrium-90 for more precise cancer treatment options [2] Group 3: Corporate Transactions and Financial Updates - WuXi AppTec has completed the sale of its subsidiary, expecting a post-tax net profit of approximately 960 million yuan, which accounts for over 10% of the company's latest audited net profit attributable to shareholders [5][6] - Guolian Minsheng has terminated a 480 million yuan fund establishment transaction, with no adverse effects on the company's finances or shareholder rights [7] - Morning Paper Industry plans to sell all shares of a target company for 3.336 billion yuan [10] Group 4: New Technologies and Innovations - GAC Group's flying car, GOVY AirCab, has entered the airworthiness certification stage and is expected to be mass-produced by 2026, aiming to create a new mode of transportation that integrates air and ground travel [17] - China Tongyuan has signed a commercial cooperation agreement with Novartis for the radiopharmaceutical product, providing a new treatment option for advanced prostate cancer patients [18]

Core Viewpoint - China Tongru (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," involving Yuanzi Gaoke Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a five-year survival rate of less than 50% [1] - The project focuses on addressing the challenges posed by neuroblastoma, which is referred to as the "king of childhood cancers," and aims to contribute to public health in China [1] Group 2: Technological Achievements - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, creating a "multimodal, low-dose, short-duration" precision diagnosis and treatment system for neuroblastoma [1] - Yuanzi Gaoke has developed the positron-emitting radiopharmaceutical sodium fluoride [18F] injection, completed Phase III clinical trials, and successfully registered it, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has also led the development of the iodine [123I] sodium solution radiopharmaceutical group standard and collaborated with the Friendship Hospital to provide a basis for standardized production of domestic radiopharmaceuticals [2] Group 3: Strategic Collaboration - Yuanzi Gaoke and the nuclear medicine department of the Friendship Hospital have established a long-term strategic partnership based on the concept of "industry-university-research-medical collaboration" [2] - The collaboration has resulted in significant advancements in radiopharmaceutical supply, research platform construction, and clinical trial promotion [2] - Moving forward, Yuanzi Gaoke will continue to focus on the field of nuclear medicine, increase investment in radiopharmaceutical research and technological innovation, and deepen cooperation with clinical institutions to enhance precision medical development [2]

Core Insights - China Tongfu (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," participated by Atomic High-Tech Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - The project focuses on addressing the challenges posed by neuroblastoma, which has a poor prognosis with a 5-year survival rate of less than 50% for high-risk patients [1] - The project aims to establish a complete independent innovation chain for neuroblastoma diagnosis and treatment, utilizing multimodal nuclear medicine molecular imaging technology [1] Group 2: Contributions of Atomic High-Tech - Atomic High-Tech has played a key role in the development of radiopharmaceuticals for neuroblastoma, including the successful registration of sodium fluoride injection, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has established a long-term strategic partnership with Friendship Hospital, focusing on collaborative innovation in radiopharmaceutical supply, research platform construction, and clinical trial advancement [2] - Future efforts will include increased investment in radiopharmaceutical research and technology innovation, aiming to enhance precision medicine and safeguard public health [2]

Core Viewpoint - The project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," completed with the participation of Yuanzi Gaoke Co., Ltd., has won the first prize of the Beijing Medical Science and Technology Award this year [1] Group 1: Project Significance - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a 5-year survival rate of less than 50% [1] - The project addresses a significant public health issue affecting children's health in China, focusing on the challenges posed by neuroblastoma, referred to as the "king of childhood cancers" [1] Group 2: Technological Innovation - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, after ten years of systematic research [1] - It has developed a multimodal, low-dose, and short-duration nuclear medicine molecular imaging precision diagnosis and treatment system for neuroblastoma, contributing Chinese wisdom and solutions to this global challenge [1]

（股份代號：1763） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於其他海外監管市場發佈的公告 公司附屬公司榮獲北京醫學科技獎一等獎 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈。 茲載列原子高科股份有限公司於2025年12月15日於全國中小企業股份轉讓系統網 站(www.neeq.com.cn)刊登的「原子高科股份有限公司關於參與「兒童神經母細胞 瘤多模態核醫學分子影像體系的建立」項目榮獲北京醫學科技獎一等獎的公告」， 僅供參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年12月15日 於 ...

格隆汇12月15日丨中国同辐(01763.HK)宣布，公司附属公司原子高科股份有限公司(「原子高科」)与诺 华医药科技(浙江)有限公司(「诺华公司」)正式签署派威妥®(鑥[177Lu]特昔维匹肽注射液)商业合作协 议。派威妥®是国内首个且目前唯一获批的靶向PSMA的放射配体疗法药物，主要用于治疗晚期前列腺 癌，未来将为患者提供延长生命并改善生活质量的全新核药治疗方案。此次签约开启了双方在创新核药 产品派威妥®方面的战略合作，原子高科将凭藉在放射性药物领域的多年合规运营经验，与诺华公司强 强联合，为医疗机构和患者提供定制化的派威妥®产品供应与解决方案，以惠及更多的患者。 ...

中国同辐(01763)发布公告，本公司附属公司原子高科股份有限公司(原子高科)与诺华医药科技(浙江)有 限公司(诺华公司)正式签署派威妥(镥[177Lu]特昔维匹肽注射液)商业合作协议(商业合作协议)。派威妥 是国内首个且目前唯一获批的靶向PSMA的放射配体疗法药物，主要用于治疗晚期前列腺癌，未来将为 患者提供延长生命并改善生活质量的全新核药治疗方案。此次签约开启了双方在创新核药产品派威妥方 面的战略合作，原子高科将凭藉在放射性药物领域的多年合规运营经验，与诺华公司强强联合，为医疗 机构和患者提供定制化的派威妥产品供应与解决方案，以惠及更多的患者。 ...

Core Viewpoint - China Tongfu (01763) announced a commercial cooperation agreement with Novartis Pharma Technology (Zhejiang) Co., Ltd. for the drug Paiweituo® (Lutetium-177-PSMA-617 injection), which is the first and only approved targeted radioligand therapy for advanced prostate cancer in China [1] Group 1: Company Collaboration - The agreement marks the beginning of a strategic partnership between China Tongfu's subsidiary, Atomic High-Tech Co., Ltd., and Novartis, focusing on the innovative nuclear medicine product Paiweituo® [1] - Atomic High-Tech will leverage its years of compliant operation experience in the field of radiopharmaceuticals to collaborate with Novartis, providing customized product supply and solutions for medical institutions and patients [1] Group 2: Product Significance - Paiweituo® aims to offer a new nuclear medicine treatment option that extends life and improves the quality of life for patients with advanced prostate cancer [1]

內幕消息 與諾華醫藥科技（浙江）有限公司簽署商業合作協議 本公告乃由中國同輻股份有限公司（「本公司」）根據香港聯合交易所有限公司證券 上市規則（「上市規則」）第13.09(2）條及香港法例第571章證券及期貨條例第XIVA 部內幕消息條文（定義見上市規則）而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 據董事經作出一切合理查詢後所深知、盡悉及確信，於本公告日期，諾華公司及 其最終實益擁有人均為獨立於本公司及其關連人士（定義見上市規則）的第三方。 商業合作協議及其項下之合作不構成本公司於上市規則第14章項下之須予公佈的 交易，亦不構成上市規則第14A章項下之關連交易。 1 股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 中國同輻股份有限公司 本公司董事（「董事」）會 ...